Did Exelixis use a 'trivial' modification to its cash cow to product hop past a patent cliff? These researchers think so

Summary

Exelixis relies heavily on cabozantinib revenue, and researchers question whether the company made trivial modifications to the drug to extend patent protection and avoid a patent cliff.